EASL Podcasts

Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically...

The following objectives will be addressed in this EASL Deep Dive episode: Have a profound knowledge of the pitfalls, limitations and difficulty of interpretation of the different tests of copper metabolism and liver copper assessments Be able to establish a diagnostic approach to Wilson’s disease, integrating clinical, laboratory, genetic and imaging tools Have a good understanding of the differe...

Steatotic liver disease (SLD) research relies heavily on preclinical models, yet no single model can fully capture the complexity of human disease. In this episode, we explore the new EASL position paper on preclinical SLD models. From MASLD and MetALD to organoids and precision-cut liver slices, we discuss the strengths, limitations, and translational relevance of today's most widely used mo...

Haemochromatosis remains one of the most common inherited metabolic disorders, yet it is frequently underdiagnosed and inconsistently managed in clinical practice. With widespread use of iron studies and genetic testing, clinicians are increasingly faced with questions around interpretation, penetrance, and clinical significance. In this podcast, we explore current challenges in diagnosis and mana...

In this episode, we discuss the first pig-to-human liver xenotransplantation and the breakthroughs behind the revival of xenotransplantation, examining its potential and remaining challenges. We also explore the accelerating field of machine perfusion, clarifying different approaches and reviewing the evidence supporting their role in organ assessment, optimisation, and DCD utilisation. Host: Sarw...

Spontaneous bacterial peritonitis (SBP) remains a major complication of cirrhosis - but rising antimicrobial resistance and emerging data are challenging long-standing practices. In this episode, we review current evidence on primary and secondary prophylaxis, resistance patterns, albumin use, and treatment strategies. How should clinicians balance prevention with antimicrobial stewardship? And wh...

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Learning Objectives To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classification To define th...

This episode explores the role of lifestyle in preventing and managing liver disease, including MASLD/MASH. Our experts discuss the impact of diet and physical activity, why lifestyle change can be difficult to start and sustain, and why small, achievable steps can still make a meaningful difference.  Host: Cyrielle Caussy Speakers:   Kate Hallsworth and Manuel Romero-Gómez  This episode is also a...

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult. In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the r...

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025. Learning objectives Select induction and maintenance treatment strategies aimed at achieving complete biochemical response Recognise and manage disease flares, treatment intolerance, and subop...

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025. Learning objectives Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guide...

In this episode our speakers share their immediate impressions and break down the key highlights shaping the management of portal hypertension and advanced liver disease. What has truly changed in practice? Where was consensus reached and where do controversies remain? Tune in for a clear, practical overview of what you need to know from Baveno VIII. Host: Thomas Marjot Speakers:   Mattias Mandorf...

This episode unpacks the updated BCLC guidelines for hepatocellular carcinoma management. Experts discuss the strengths and limitations of the BCLC model in an era of rapidly evolving systemic therapies and personalised care, sharing real-world examples of when the algorithm helps and when clinical practice diverges. Host: Mattias Mandorfer Speakers:   Marco Sanduzzi, Lorenza Rimassa This episode...

As deaths from advanced chronic liver disease rise, many patients never receive timely palliative care. In this episode, we explore why early, holistic support is essential in advanced liver disease and HCC, and unpack key recommendations from the new EASL Position Paper to help reduce suffering and improve quality of life. Host:   Debbie Shawcross Speakers: Patrizia-Künzler-Heule, Sumita Verma  T...

This episode explores whether MetALD is a meaningful clinical entity or an unnecessary complication. Experts discuss the overlap between metabolic dysfunction and alcohol use, the challenges of applying the MetALD definition in practice, and its impact on classification, guidelines, drug development, and patient care.  Host:   Thomas Marjot Speakers:   Mary Rinella ,  Aleksander Krag  This episode...

EASL’s Secretary General and Vice Secretary General share an open conversation on the challenges and opportunities for women in hepatology. The episode explores the role of mentorship across career stages and reflects on the journey toward EASL’s first female Secretary General, offering insights on leadership and change in the field. Host: Maja Thiele Speakers: Debbie Shawcross, Ana Lleo This epis...

In collaboration with the Indian National Association for the Study of the Liver (INASL), hepatologists from South Asia and North America/Europe take listeners inside their liver wards to explore how regional context shapes acute liver care. From admission patterns to alcohol use, infections, DILI, nutrition, and access to transplant, the episode highlights key differences and opportunities for sh...

This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC). Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways. Moderator: David Jones Speakers: Marco Carbone, Bettina Hansen, and An...

How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention. Moderator: Shira Zelber Sagi Spea...

What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond. Moderator: Debbie Shawcross Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin All EASL Studio Podcasts are available on EASL Campus ....

For World Antimicrobial Awareness Week 2025 ( “Act Now: Protect Our Present, Secure Our Future” ), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance. Moderator: Debbie Shawcross Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka All EASL Studio Podcasts are available on EASL Campus . Click here to see...

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls. Moderator: Mattias Mandorfer  Speakers: Tobias Böttler, Virginia Hernández-Ge...

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC? Moderator: Debbie Shawcross Speakers: Cynthia Levy, Stephen Rossi,...

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or...

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do...